Ralph E. Hurd1, Yi-Fen Yen1, Dirk Mayer2,3, Albert Chen4, David Wilson5, Susan Kohler6, James Tropp1, Robert Bok5, Daniel Vigneron5, John Kurhanewicz5, Daniel Spielman2, Adolf Pfefferbaum3,7
1Applied Science Laboratory, GE Healthcare, Menlo Park, CA, USA; 2Department of Radiology, Stanford, Stanford, CA, USA; 3SRI International, Menlo Park, CA, USA; 4Applied Science Laboratory, GE Healthcare, Toronto, Ontario, Canada; 5Department of Radiology, UCSF, San Francisco, CA, USA; 6Union College, Schenectady, NY, USA; 7Psychiatry, Stanford, Stanford, CA, USA
Formulation, polarization and dissolution conditions were developed to obtain a stable hyperpolarized solution of 1-[13C]-ethyl-pyruvate. A maximum tolerated dose and injection rate were determined, and 13C spectroscopic imaging was used to compare the uptake of hyperpolarized 1-[13C]-ethyl pyruvate relative to hyperpolarized 1-[13C]- pyruvate into anesthetized rat brain. Hyperpolarized 1-[13C]-ethyl pyruvate metabolic imaging in normal brain is demonstrated in this feasibility study.